
Proceedings of the WFH’s Third Global Forum on the Safety and Supply of Hemophilia Treatment Products
A summary of discussions held at the World Federation of Hemophilia’s Global Forum on the Safety and Supply of Hemophilia
Year: 2016
Language: Polish
Author(s): World Federation of Hemophilia
Format: Document
Also Available In: English, Spanish, French, Arabic, Russian, Simplified Chinese
This is not an official WFH translation. This resource has been translated with permission by a WFH National Member Organization (NMO), and is shared here with their kind permission. Translating organizations are encouraged to have translations reviewed by local experts, the WFH is not responsible for the translation or for any errors or changes to content from the original English edition. Patient organizations interested in translating a WFH resource must first obtain permission from the WFH, available here.
Desmopressin (DDAVP) may be the treatment of choice for patients with mild or moderate hemophilia A and type 1 von Willebrand disease (VWD). This Fact Sheet presents essential information about this synthetic medicine which costs much less than plasma products or recombinant clotting factor concentrates, carries no risk of transmission of viral infections, and is on the World Health Organization’s (WHO) Model List of Essential Medicines (EML).

A summary of discussions held at the World Federation of Hemophilia’s Global Forum on the Safety and Supply of Hemophilia

This resource has also been translated into the following languages, with permission from the WFH, by NMOs: Farsi A description of

Also Available In: English, Spanish This is not an official WFH translation. This resource has been translated with permission by

Helps identify effective treatment strategies for hemophilia. Topics include delivery of treatment, on-demand treatment, prophylaxis, immune tolerance, and factor assays.

The Hemophilia Treatment Centre (HTC) Twinning program pairs emerging HTCs with established ones to help increase the levels of diagnosis

A summary of discussions held at the World Federation of Hemophilia’s Global Forum on the Safety and Supply of Hemophilia